Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$4.6 - $7.8 $299,395 - $507,670
-65,086 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$6.1 - $10.2 $112,593 - $188,271
18,458 Added 39.59%
65,086 $43,000
Q3 2021

Nov 15, 2021

SELL
$8.2 - $12.4 $1.72 Million - $2.61 Million
-210,190 Reduced 81.84%
46,628 $43,000
Q2 2021

Aug 16, 2021

SELL
$11.8 - $18.2 $4.8 Million - $7.4 Million
-406,383 Reduced 61.28%
256,818 $306,000
Q1 2021

May 17, 2021

BUY
$15.2 - $25.0 $9.36 Million - $15.4 Million
616,026 Added 1305.83%
663,201 $1.07 Million
Q4 2020

Feb 16, 2021

BUY
$11.2 - $27.7 $528,360 - $1.31 Million
47,175 New
47,175 $98,000

About Cellectar Biosciences, Inc.


  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $1.47M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.